Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clazosentan - Idorsia Pharmaceuticals

Drug Profile

Clazosentan - Idorsia Pharmaceuticals

Alternative Names: ACT-108475; AXV 034; AXV 034343; Pivlaz

Latest Information Update: 30 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical; Roche
  • Developer Idorsia Pharmaceuticals
  • Class Anti-ischaemics; Dioxanes; Neuroprotectants; Pyridines; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cerebral vasospasm
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cerebral vasospasm

Most Recent Events

  • 22 Mar 2019 Idorsia Pharmaceuticals temporarily halts a phase III trial in Cerebral vasospasm in Germany, Sweden, Spain (EudraCT2018-000241-39)
  • 26 Oct 2018 Idorsia Pharmaceuticals completes a phase I trial (In volunteers) in Netherlands (IV) (NCT03657446)
  • 18 Oct 2018 Idorsia Pharmaceuticals initiates a phase I trial in Healthy volunteers in the Netherlands (IV) (NCT03657446)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top